AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: SYMBICORT (AstraZeneca) (symbicort.com)
SYMBICORT delivers high medical substance through its mandatory safety disclosures but fails technically with a ‘Loading’ heading structure and generic schema. The BS score is low because pharma regulations prevent the most egregious marketing lies, but the technical execution is a lazy template. It is a site that prioritizes legal compliance over informative patient engagement.
Immediately replace the H2 Loading…… tags with descriptive, keyword-rich headings that summarize the sections. Update the WebSite schema to correctly identify the brand name as ‘SYMBICORT’ and add Organization schema for AstraZeneca with sameAs links to official profiles. Insert direct links to peer-reviewed clinical trial results and the full ClinicalTrials.gov record to back the ‘Breathe Better’ claim. Differentiate the sub-pages by replacing the duplicated homepage content with unique, page-specific substance about cost programs and asthma-specific pathology.
Information density is split between low-substance marketing headers and high-substance regulatory text. The H1 Discover how SYMBICORT may help you BREATHE BETTER is a classic power-word claim, but it is immediately anchored by a specific price point of $35 per month and a dense 2,000-word block of Important Safety Information. However, the site suffers from extreme concept repetition, with the same ‘Approved Uses’ and ‘Safety Information’ blocks duplicated across all four analyzed URLs, providing zero additional information as the user moves deeper into the site.
If your @id chain is broken, your entire knowledge graph collapses into isolated nodes. Check your AI visible entity graph with a free one page structured data interpretation.
There is virtually zero semantic drift in the messaging because every page analyzed contains identical content. While this ensures the ‘Breathe Better’ promise is consistent, it represents a technical failure of content strategy where the Cost Assistance and Asthma sub-pages fail to deliver specific tailored substance, instead repeating the homepage template. The H2 Loading…… tags across all pages indicate a significant disconnect between the intended heading structure and the delivered technical content.
Move beyond vague agency reporting and visualize your surgical implementation plan. Order an Executive SEO Strategy and stop relying on superficial keyword tracking.
The site avoids common trust theatre patterns such as unverified customer testimonials or fake review counts (review_count is 0). However, it relies on ‘Prescribing Information’ as a primary proof path without providing direct, verified outbound links to clinical trial data or peer-reviewed studies within the provided crawl data. The absence of verified proof links (proof_links_count: 0) creates a gap between the brand’s medical claims and the accessible forensic evidence for a patient.
The ratio of proof to claims is healthy due to the legally required safety disclosures, which act as technical substance. The site provides specific age thresholds (6 years and older) and exact pricing ($35), which are high-proof markers. However, the lack of external citations for clinical efficacy claims across the four pages reduces the overall proof density to a lower level than expected for a leading pharma brand.
To examine how structural entropy affects chunking and retrieval, review the Moz Semantic HTML audit. View the Moz Semantic HTML Audit for a complete example of heading logic, landmark integrity, and DOM depth diagnostics.
The site uses a boilerplate pharmaceutical template that is highly predictable, featuring the ‘Important Safety Information’ scroll-box and ‘Approved Uses’ sections. Clichés like ‘Discover’ and ‘Breathe Better’ are present, but their impact is neutralized by the highly specific drug dosage (160/4.5 mcg) and named manufacturer (AstraZeneca). The value proposition is brand-specific and cannot be copy-pasted onto a competitor, though the layout is an industry commodity.
There is a significant authority gap in the site’s technical identity. The schema_json identifies the site name as Multibrand rather than SYMBICORT or AstraZeneca, which is a major red flag for a high-authority medical entity. Additionally, the expert footprint is limited to a ‘Talk to a Nurse’ call-to-action without providing named medical professionals, credentials, or Person schema to verify the authority of the support being offered.
The primary claim of ‘Breathe Better’ is moderately disconnected from the evidence on the page, as it is presented with the vague qualifier ‘results may vary.’ While the site provides a detailed list of side effects and pharmacological mechanisms (ICS/LABA combination), it fails to demonstrate the performance with specific percentage improvements from clinical trials. The marketing tone is authoritative, but the data provided is defensive (safety-first) rather than performance-oriented.
Medical Devices, Pharma & Biotech BS: SYMBICORT (AstraZeneca) (symbicort.com)
The content strictly aligns with the Pharmaceutical and Biotech industry, characterized by the heavy presence of regulatory-mandated Important Safety Information (ISI) and specific therapeutic indications for Asthma and COPD. The presence of budget-focused patient assistance programs and prescribing information references confirms the pharmaceutical nature of the site.
The access layer decides whether your content even enters the model's world. Review the Crawlability & Indexation Framework to see how AI visible content differs from what humans see in the browser.
“The score of 30 is driven primarily by technical authority gaps and content repetition. The Information Density pillar (8/30) reflects the high repetition of identical content across URLs. The Identity and Authority pillar (9/15) is the highest penalty source due to the broken 'Loading' headings and the generic 'Multibrand' schema identity.”
Analysis Disclosure & Source Attribution
Snapshot Date: June 19, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at SYMBICORT (AstraZeneca) to view the most current version of their content and see directly what the company offers.